RCN Pareto Strategic Allocation ETF (NYSEARCA:PRTO) Short Interest Update

RCN Pareto Strategic Allocation ETF (NYSEARCA:PRTO) saw a large decline in short interest during the month of June. As of June 30th, there was short interest totaling 338 shares, a decline of 82.9% from the June 15th total of 1,978 shares. Currently, 0.0% of the shares of the company are sold short. Based on an average daily volume of 503 shares, the short-interest ratio is presently 0.7 days.

RCN Pareto Strategic Allocation ETF Price Performance

PRTO traded down $0.04 during trading on Friday, hitting $27.58. The stock had a trading volume of 407 shares. RCN Pareto Strategic Allocation ETF has a one year low of $24.68 and a one year high of $28.16. The company has a market capitalization of $611.70 million, a PE ratio of -28.73 and a beta of 0.60.

Proteon Therapeutics was a biopharmaceutical company focused on developing treatments for patients with kidney and vascular diseases. The company’s research and development efforts centered on therapies designed to address severe and life-threatening conditions, particularly those related to renal disease and vascular access for hemodialysis patients.

One of Proteon Therapeutics’ best-known product candidates was vonapanitase, an investigational enzyme developed to improve vascular access outcomes in patients with end-stage renal disease who require hemodialysis.